title: Biogenetic tests emerge from their chrysalis.
abstract: As technology improves, barriers to payment are beginning to fall for costly diagnostic tests that may identify good candidates for even pricier therapies. Part 1 of 2.
authors.affiliation: Senior contributing editor John Carroll is a freelance writer and is the editor of Fierce Biotech.
authors.forename: John
authors.initials: J
authors.lastname: Carroll